Você está na página 1de 8

03/02/2015

Reboxetine: A Novel Antidepressant Kadhe N G, Chillar A J, Deshmukh Y A ­ J Postgrad Med

03/02/2015 Reboxetine: A Novel Antidepressant Kadhe N G, Chillar A J, Deshmukh Y A ­ JAbout Latest Back­Issues Article Submission Open access journal indexed with Index Medicus & ISI's SCI Users online: 86 Home | Subscribe | Feedback | Login Resources Sections Etcetera Contact NAVIGATE Here Search GO :: Next article :: Previous article DRUG REVIEW Year : 2003 | Volume : 49 | Issue : 4 | Page : 373­375 :: Table of Contents Reboxetine: A Novel Antidepressant RESOURCE Links :: Similar in PUBMED :: Search Pubmed for NG Kadhe , AJ Chillar , YA Deshmukh T. N. Medical College & B.Y.L.Ch. Nair Hospital, Mumbai Central, Mumbai, India Kadhe N G Chillar A J Correspondence Address : Deshmukh Y A N G Kadhe Department of Pharmacology, T. N. Medical College & B.Y.L.Ch. :: Search in Google Scholar Nair Hospital, Mumbai Central, Mumbai for India Kadhe N G Chillar A J Deshmukh Y A 1 :: Article in PDF (138 KB) :: Citation Manager :: Access Statistics :: Reader Comments :: Email Alert * :: Add to My List * PMID: 14699244 * Registration required (free) IN THIS Article :: Mechanism of Action :: Pharmacokinetic ... :: Dose :: ADRs :: Drug Interactions :: Comparison of Ef... :: Comparison of Sa... :: Other indications How to cite this article: Kadhe N G, Chillar A J, Deshmukh Y A. Reboxetine: A Novel Antidepressant. J Postgrad Med 2003;49:373­5 How to cite this URL: Kadhe N G, Chillar A J, Deshmukh Y A. Reboxetine: A Novel Antidepressant. J Postgrad Med [serial online] 2003 [cited 2015 Feb 2];49:373­5. Available from: http://www.jpgmonline.com/text.asp? 2003/49/4/373/4988 :: Conclusion :: References Depression is a common and disabling disorder. The World Health Organisation has ranked depression fourth in a list of the most urgent http://www.jpgmonline.com/article.asp?issn=0022­3859;year=2003;volume=49;issue=4;spage=373;epage=375;aulast=Kadhe 1/8 " id="pdf-obj-0-7" src="pdf-obj-0-7.jpg">
Article Submission
Article
Submission

Open access journal indexed with Index

Medicus & ISI's SCI

Users online: 86

NAVIGATE Here

Search GO :: Next article
Search
GO
:: Next article

DRUG REVIEW

03/02/2015 Reboxetine: A Novel Antidepressant Kadhe N G, Chillar A J, Deshmukh Y A ­ JAbout Latest Back­Issues Article Submission Open access journal indexed with Index Medicus & ISI's SCI Users online: 86 Home | Subscribe | Feedback | Login Resources Sections Etcetera Contact NAVIGATE Here Search GO :: Next article :: Previous article DRUG REVIEW Year : 2003 | Volume : 49 | Issue : 4 | Page : 373­375 :: Table of Contents Reboxetine: A Novel Antidepressant RESOURCE Links :: Similar in PUBMED :: Search Pubmed for NG Kadhe , AJ Chillar , YA Deshmukh T. N. Medical College & B.Y.L.Ch. Nair Hospital, Mumbai Central, Mumbai, India Kadhe N G Chillar A J Correspondence Address : Deshmukh Y A N G Kadhe Department of Pharmacology, T. N. Medical College & B.Y.L.Ch. :: Search in Google Scholar Nair Hospital, Mumbai Central, Mumbai for India Kadhe N G Chillar A J Deshmukh Y A 1 :: Article in PDF (138 KB) :: Citation Manager :: Access Statistics :: Reader Comments :: Email Alert * :: Add to My List * PMID: 14699244 * Registration required (free) IN THIS Article :: Mechanism of Action :: Pharmacokinetic ... :: Dose :: ADRs :: Drug Interactions :: Comparison of Ef... :: Comparison of Sa... :: Other indications How to cite this article: Kadhe N G, Chillar A J, Deshmukh Y A. Reboxetine: A Novel Antidepressant. J Postgrad Med 2003;49:373­5 How to cite this URL: Kadhe N G, Chillar A J, Deshmukh Y A. Reboxetine: A Novel Antidepressant. J Postgrad Med [serial online] 2003 [cited 2015 Feb 2];49:373­5. Available from: http://www.jpgmonline.com/text.asp? 2003/49/4/373/4988 :: Conclusion :: References Depression is a common and disabling disorder. The World Health Organisation has ranked depression fourth in a list of the most urgent http://www.jpgmonline.com/article.asp?issn=0022­3859;year=2003;volume=49;issue=4;spage=373;epage=375;aulast=Kadhe 1/8 " id="pdf-obj-0-49" src="pdf-obj-0-49.jpg">

Year : 2003 | Volume : 49 | Issue : 4 | Page : 373­375

Reboxetine: A Novel Antidepressant

RESOURCE Links

:: Search Pubmed for

T. N. Medical College & B.Y.L.Ch. Nair Hospital, Mumbai Central,

Mumbai, India

  • Correspondence Address:

  • N G Kadhe

 

Department of Pharmacology, T. N. Medical College & B.Y.L.Ch.

:: Search in Google Scholar

Nair Hospital, Mumbai Central, Mumbai

for

India

Kadhe N G Chillar A J Deshmukh Y A 1 :: Article in PDF (138 KB)
Kadhe N G
Chillar A J
Deshmukh Y A
1
:: Article in PDF (138 KB)

PMID: 14699244

03/02/2015 Reboxetine: A Novel Antidepressant Kadhe N G, Chillar A J, Deshmukh Y A ­ JAbout Latest Back­Issues Article Submission Open access journal indexed with Index Medicus & ISI's SCI Users online: 86 Home | Subscribe | Feedback | Login Resources Sections Etcetera Contact NAVIGATE Here Search GO :: Next article :: Previous article DRUG REVIEW Year : 2003 | Volume : 49 | Issue : 4 | Page : 373­375 :: Table of Contents Reboxetine: A Novel Antidepressant RESOURCE Links :: Similar in PUBMED :: Search Pubmed for NG Kadhe , AJ Chillar , YA Deshmukh T. N. Medical College & B.Y.L.Ch. Nair Hospital, Mumbai Central, Mumbai, India Kadhe N G Chillar A J Correspondence Address : Deshmukh Y A N G Kadhe Department of Pharmacology, T. N. Medical College & B.Y.L.Ch. :: Search in Google Scholar Nair Hospital, Mumbai Central, Mumbai for India Kadhe N G Chillar A J Deshmukh Y A 1 :: Article in PDF (138 KB) :: Citation Manager :: Access Statistics :: Reader Comments :: Email Alert * :: Add to My List * PMID: 14699244 * Registration required (free) IN THIS Article :: Mechanism of Action :: Pharmacokinetic ... :: Dose :: ADRs :: Drug Interactions :: Comparison of Ef... :: Comparison of Sa... :: Other indications How to cite this article: Kadhe N G, Chillar A J, Deshmukh Y A. Reboxetine: A Novel Antidepressant. J Postgrad Med 2003;49:373­5 How to cite this URL: Kadhe N G, Chillar A J, Deshmukh Y A. Reboxetine: A Novel Antidepressant. J Postgrad Med [serial online] 2003 [cited 2015 Feb 2];49:373­5. Available from: http://www.jpgmonline.com/text.asp? 2003/49/4/373/4988 :: Conclusion :: References Depression is a common and disabling disorder. The World Health Organisation has ranked depression fourth in a list of the most urgent http://www.jpgmonline.com/article.asp?issn=0022­3859;year=2003;volume=49;issue=4;spage=373;epage=375;aulast=Kadhe 1/8 " id="pdf-obj-0-140" src="pdf-obj-0-140.jpg">

* Registration required (free)

IN THIS Article

:: Mechanism of Action

:: Pharmacokinetic ...

:: Dose

:: ADRs

:: Drug Interactions

:: Comparison of Ef...

:: Comparison of Sa...

:: Other indications

How to cite this article:

Kadhe N G, Chillar A J, Deshmukh Y A. Reboxetine: A Novel

Antidepressant. J Postgrad Med 2003;49:373­5

How to cite this URL:

Kadhe N G, Chillar A J, Deshmukh Y A. Reboxetine: A Novel

Antidepressant. J Postgrad Med [serial online] 2003 [cited 2015 Feb

:: Conclusion

:: References

Depression is a common and disabling disorder. The World Health

Organisation has ranked depression fourth in a list of the most urgent

03/02/2015

Reboxetine: A Novel Antidepressant Kadhe N G, Chillar A J, Deshmukh Y A ­ J Postgrad Med

Article Access Statistics

Viewed

29735

Printed

653

Emailed

42

PDF Downloaded

364

Comments

Cited by others

4

health problems world wide.[1] Depression has major effects on

economic productivity, individual well being and social functioning,

around the globe. It is a huge burden on individuals, families, and

society. The lifetime risk for major depression has been estimated to be

7%­12% for men and 20%­25% for women.[1],[3]

According to the Biogenic Monoamine theory of Schildkraut (1965),

depression results due to impairment or dysregulation of aminergic

transmission.[1] Others suggest that though noradrenaline and

Total downloads in last 2 months

Feb 4 2015 Jan 78 2015
Feb
4
2015
Jan
78
2015

serotoninergic systems are involved, the specific impairment that

underlies depression is unclear and is likely to vary among patients.[4]

Medical treatment for depression favors prescription antidepressant

drugs that work by increasing neurotransmission for one or more of the

monoamines­serotonin, norepinephrine, or dopamine. Before 1980,

antidepressant treatment consisted primarily of the tricyclics

antidepressants (TCADs), monoamine oxidase inhibitors (MAOI), and

lithium. The antidepressant properties of these medications are

attributed to modulation of noradrenergic and serotonergic function,

but they also have many side effects due to binding to multiple

unrelated receptors. The tricyclics antagonize muscarinic, H1

histaminic, and a1 adrenergic receptors causing constipation, urinary

retention, dry mouth, sedation, and postural hypotension.5 In addition

to these, the monoamine oxidase inhibitors have the added risk of

potentially severe hypertensive crisis due to pressor effects of dietary

tyramine, which requires dietary restrictions. This risk is much lower

with the newer reversible inhibitors of monoamine oxidase. Both the

tricyclics and the monoamine oxidase inhibitors can be lethal in

overdose, and the monoamine oxidase inhibitors interact dangerously

with several over the counter and prescription drugs.

In the late 1980's a important class of antidepressant was introduced,

the selective serotonin reuptake inhibitors (SSRIs), which includes

fluvoxamine, fluoxetine, sertraline, paroxetine, and citalopram. This

class has become a mainstay of antidepressant treatment because of

substantial advantages over the tricyclics and monoamine oxidase

inhibitors in safety, tolerability, and ease of dosing. The SSRI's also

have limitations , especially response failure in many of those most

severely affected. Many patients experience side effects like

gastrointestinal complaints, nervousness and agitation, sexual

dysfunction, and weight gain with long term use.[5]

All these lead to difficulty in long term treatment and non compliance.

Hence, one of the most important goals in the pharmacological

treatment of depression is to provide the patients with highly

efficacious drugs that have few side effects, low or no toxicity and a

high level of tolerability.

Reboxetine is a selective noradrenaline reuptake inhibitor (NaRI), the

first drug of new antidepressant class introduced in 1997. Reboxetine

is a a­ ariloxybenzyl derivative of morpholine.

:: Mechanism of Action

03/02/2015 Reboxetine: A Novel Antidepressant Kadhe N G, Chillar A J, Deshmukh Y A ­ J[Add] Cited by others 4 health problems world wide. [1] Depression has major effects on economic productivity, individual well being and social functioning, around the globe. It is a huge burden on individuals, families, and society. The lifetime risk for major depression has been estimated to be 7%­12% for men and 20%­25% for women. [1] , [3] According to the Biogenic Monoamine theory of Schildkraut (1965), depression results due to impairment or dysregulation of aminergic transmission. [1] Others suggest that though noradrenaline and Total downloads in last 2 months Feb 4 2015 Jan 78 2015 serotoninergic systems are involved, the specific impairment that underlies depression is unclear and is likely to vary among patients. [4] Medical treatment for depression favors prescription antidepressant drugs that work by increasing neurotransmission for one or more of the monoamines­serotonin, norepinephrine, or dopamine. Before 1980, antidepressant treatment consisted primarily of the tricyclics antidepressants (TCADs), monoamine oxidase inhibitors (MAOI), and lithium. The antidepressant properties of these medications are attributed to modulation of noradrenergic and serotonergic function, but they also have many side effects due to binding to multiple unrelated receptors. The tricyclics antagonize muscarinic, H1 histaminic, and a1 adrenergic receptors causing constipation, urinary retention, dry mouth, sedation, and postural hypotension.5 In addition to these, the monoamine oxidase inhibitors have the added risk of potentially severe hypertensive crisis due to pressor effects of dietary tyramine, which requires dietary restrictions. This risk is much lower with the newer reversible inhibitors of monoamine oxidase. Both the tricyclics and the monoamine oxidase inhibitors can be lethal in overdose, and the monoamine oxidase inhibitors interact dangerously with several over the counter and prescription drugs. In the late 1980's a important class of antidepressant was introduced, the selective serotonin reuptake inhibitors (SSRIs), which includes fluvoxamine, fluoxetine, sertraline, paroxetine, and citalopram. This class has become a mainstay of antidepressant treatment because of substantial advantages over the tricyclics and monoamine oxidase inhibitors in safety, tolerability, and ease of dosing. The SSRI's also have limitations , especially response failure in many of those most severely affected. Many patients experience side effects like gastrointestinal complaints, nervousness and agitation, sexual dysfunction, and weight gain with long term use. [5] All these lead to difficulty in long term treatment and non compliance. Hence, one of the most important goals in the pharmacological treatment of depression is to provide the patients with highly efficacious drugs that have few side effects, low or no toxicity and a high level of tolerability. Reboxetine is a selective noradrenaline reuptake inhibitor (NaRI), the first drug of new antidepressant class introduced in 1997. Reboxetine is a a­ ariloxybenzyl derivative of morpholine. :: Mechanism of Action http://www.jpgmonline.com/article.asp?issn=0022­3859;year=2003;volume=49;issue=4;spage=373;epage=375;aulast=Kadhe 2/8 " id="pdf-obj-1-152" src="pdf-obj-1-152.jpg">

03/02/2015

Reboxetine: A Novel Antidepressant Kadhe N G, Chillar A J, Deshmukh Y A ­ J Postgrad Med

Reboxetine is a selective inhibitor of noradrenaline reuptake. It inhibits

noradrenaline reuptake invitro to a similar extent to the tricyclic

antidepressant desmethylimipramine. Reboxetine does not affect

dopamine or serotonin reuptake[5] and it has low in vivo and invitro

affinity for adrenergic, cholinergic, histaminergic, dopaminergic and

serotonergic receptors.[6]

:: Pharmacokinetic Properties

03/02/2015 Reboxetine: A Novel Antidepressant Kadhe N G, Chillar A J, Deshmukh Y A ­ J

Reboxetine is rapidly and extensively absorbed following oral

administration. Maximum plasma concentration of reboxetine is

reached in 2­2.5 hours after a 4 mg oral dose in healthy volunteers.

Reboxetine has linear pharmacokinetics across the normal dose range.

[5] Steady state plasma concentrations are reached within 5 days of

starting therapy. Reboxetine is 98 % bound to plasma proteins,

predominantly the a1­ acid glycoprotein.[6] Reboxetine is metabolized

by dealkylation , hydroxylation and oxidation followed by glucuronide

or sulphate conjugation.[7] It is metabolized by the cytochrome P450

CYP isoenzyme 3A4.[1] Compounds that decrease the activity of this

isoenzyme are likely to increase the plasma concentrations of

reboxetine. Reboxetine has a relatively short elimination half life of

12.5 hours and therefore is given twice daily. Elimination is mainly via

urine with 10% excreted as unchanged drug. Elderly individuals,

patients with hepatic and renal insufficiency have a higher plasma

concentration, a longer t1/2, and reduced clearance of reboxetine.[6]

:: Dose

03/02/2015 Reboxetine: A Novel Antidepressant Kadhe N G, Chillar A J, Deshmukh Y A ­ J

Initial dose for adults is 4 mg twice daily. For most patients an increase

in dose is not necessary. However, if needed, the dose may be

increased to a total of 10­12 mg/day in two doses after 3 weeks. In

elderly patients or those with hepatic or renal impairment, therapy may

be initiated at 2 mg twice daily and increased to a maximum of 6

mg/day in two doses after 3 weeks.[2],[5]

:: ADRs

03/02/2015 Reboxetine: A Novel Antidepressant Kadhe N G, Chillar A J, Deshmukh Y A ­ J

Due to selectivity of reboxetine for norepinephrine, it is generally well

tolerated with a benign side effect profile. The side effects reported are

dry mouth, constipation, urinary hesitancy and/or retention and other

anticholinergic side effects; CNS side effects like agitation, anxiety,

nervouness, day time somnolence. A small percentage of patients have

reported sexual dysfunction.[2],[5],[7]

03/02/2015

Reboxetine: A Novel Antidepressant Kadhe N G, Chillar A J, Deshmukh Y A ­ J Postgrad Med

:: Drug Interactions

:: Drug Interactions

Clinical data on interactions with reboxetine is limited, but

concomittant administration with MAO inhibitors, tricyclic

antidepressants, SSRIs, antipychotics, antiarrythmics, cyclosporin,

azole antifungals, and macrolide antibiotics[5],[7] should be avoided.

:: Comparison of Efficacy with other antidepressants

:: Comparison of Efficacy with other antidepressants

In clinical trials, Reboxetine has been shown to be at least as effective

as tricyclic antidepressants desipramine and imipramine in the

treatment of patients with major depressive disorder in the adult and

the elderly population and offers a significant advantage over

imipramine in the treatment of melancholic patients.[6],[8]

Reboxetine is as effective as SSRI fluoxetine.[8],[9] Reboxetine offers

significant advantages over fluoxetine in terms of social functioning.

Certain symptoms within the depressive syndrome respond better to

NaRIs , whereas other symptoms respond better to SSRIs.

Noradrenergic neurons are involved in mood, arousal, appetite, reward

and drives. Dopamine is important for pleasure, sex, pychomotor

activity; Serotonin in regulatory control of affects, aggression, sleep

and appetite. Norepinephrine depletion studies suggest that while

norepinephrine reuptake inhibition may improve all core symptoms of

depression, norepinephrine regulation may be most closely correlated

with patient improvements in energy, interest, concentration, agitation,

helplessness, and hopelessness. Reboxetine, therefore, through its

mechanism of action may be useful for drive deficient anergic states[5]

where the capacity for sustained motivation is lacking; for melancholic

depressives with a poor ability to cope with stress;[8] and those with

comorbid anxiety[2]. In a sub­analysis of patients with severe

depression indicated that, reboxetine had superior efficacy compared

with fluoxetine.[8],[9],[10]

Remission rates were similar for reboxetine, imipramine and

fluoxetine. The onset of action 2­3 weeks is similar to other

antidepressants.[6]

:: Comparison of Safety & Tolerability with other antidepressants

03/02/2015 Reboxetine: A Novel Antidepressant Kadhe N G, Chillar A J, Deshmukh Y A ­ J

Reboxetine has a significantly improved adverse event profile as

compared to TCADs.[8] When compared with imipramine, in patients

with severe depression and melancholy the frequency of

discontinuation due to adverse events was lower in the reboxetine­

treated and the cumulative risk of development of dry mouth,

hypotension and/or related symptoms and tremor was significantly

higher on imipramine than on reboxetine.[11]

03/02/2015

Reboxetine: A Novel Antidepressant Kadhe N G, Chillar A J, Deshmukh Y A ­ J Postgrad Med

Data from patients treated with reboxetine show that reboxetine has no

significant cardiovascular effects, a low potential for drug interactions,

causes no significant impairment of cognitive or motor function and no

increase in suicidal ideation. In contrast to certain serotonergic drugs,

there is no evidence of any withdrawal syndrome upon abrupt

discontinuation or tapering of reboxetine treatment. Sexual dysfunction

appears in only a small fraction of the patients and mainly with doses

higher than 8 mg daily.[12]

Elderly patients are particularly susceptible to the potential side effects

of current antidepressants due to age related physiologic changes.

Reboxetine 4 mg/day, increasing to 6 mg/day on the basis of individual

patient tolerability, may be considered safe dose range for testing the

efficacy and tolerability of reboxetine in long term controlled clinical

trials in elderly patients with depression.[13]

:: Other indications

:: Other indications

Reboxetine has been found useful in narcolepsy,[14] Panic disorders,

[1],[15] treatment of depression in patients with Parkinsons disease.

[16]

:: Conclusion

:: Conclusion

Noradrenaline has a major impact on the symptomatology of

depression. It is involved in enhancing vigilance, attention, and drive.

The determination of outcome of treatment of depression is important

both for the symptoms of depression and social functioning.[17]

Hence, noradrenaline reuptake inhibitors may have a greater impact on

drive, motivation, energy and social functioning. A comprehensive

series of clinical trials have compared the unique selective NaRI

reboxetine with placebo and with the TCADs imipramine and

desipramine, as well as with the SSRI fluoxetine. Reboxetine is clearly

effective in both the short and the long term compared with placebo.

Against comparator antidepressants, reboxetine is at least as effective

in the treatment of patients with major depressive disorder in the adult

and the elderly population and offers a significant advantage over

imipramine in the treatment of melancholic patients. It has a

significantly improved adverse event profile compared with TCADs.

In severely depressed patients, reboxetine was significantly more

effective than fluoxetine. Reboxetine also offers significant advantages

over fluoxetine in terms of social functioning.[8],[18]

Reboxetine, the first selective NaRI , with its selective mechanism of

action, offering equivalent or even better efficacy in certain patient

groups and acceptable tolerability profile is a valuable addition to the

existing armamentarium of drugs used for the treatment of depression.

03/02/2015

Reboxetine: A Novel Antidepressant Kadhe N G, Chillar A J, Deshmukh Y A ­ J Postgrad Med

:: References

03/02/2015 Reboxetine: A Novel Antidepressant Kadhe N G, Chillar A J, Deshmukh Y A ­ JPUBMED ] [ FULLTEXT ] 6. Holm KJ, Spencer CM. Reboxetine A Review of its Use in Depression. CNS Drugs 1999;12:65­83. 7. Martin Dale. The complete drug reference. Parfitt K, editor. 32nd edn. Pharmaceutical Press; 1999. pp. 307. 8. Montgomery SA. Chairman's overview. The place of reboxetine in antidepressant therapy. J Clin Psychiatry 1998;59:26­9. [ PUBMED ] 9. Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: a double­blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999;14:73­80. [ PUBMED ] 10. Venditti LN, Arcelus A, Birnbaum H, Greenberg P, Barr CE, RowlandC, et al. The impact of antidepressant use on social functioning: reboxetine versus fluoxetine. Int Clin Psychopharmacol 2000;15:279­89. 11. Berzewski H, Van Moffaert M, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double­ blind study in patients suffering from major depressive offsodes. Eur Neuropsychopharmacol 1997;Suppl 1:S37­47; (discussion S71­3). 12. Tanum L Reboxetine: tolerability and safety profile in patients with major depression. Acta Psychiatr Scand Suppl 2000;402:37­40. 13. AndreoliV, Carbognin G, Abati A , Vantini G. Reboxetine in the treatment of depression in the elderly: pilot study. J Geriatr Psychiatry Neurol 1999;12:206­10. 14. Larrosa O, de la Llave Y, Bario S,Granizo JJ, Garcia­Borreguero D. Stimulant and anti cataplectic effects of reboxetine in patients with narcolepsy: a pilot study Sleep 2001;24:282­5. 15. Dannon PN, Iancu I, Grunhaus L. The efficacy of reboxetine in the treatment ­refractory patients with panic disorder: an open label study. Human Psychopharmacol 2002;17:329­33. 16. Lemke MR. Effect of reboxetine on depression in Parkinson's disease patients. J Clin Psychiatry 2002;63:300­4. 17. Healy D. Reboxetine: its effects as measured by the Social Adaptation Self evaluation Scale. Acta Psychiatr Scand Suppl 2000;402: 18. 45­51. [ PUBMED ] 19. Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: http://www.jpgmonline.com/article.asp?issn=0022­3859;year=2003;volume=49;issue=4;spage=373;epage=375;aulast=Kadhe 6/8 " id="pdf-obj-5-9" src="pdf-obj-5-9.jpg">
  • 1. Akisal HS, Blazer DG, Kelsoe ME, et al. Mood Disorders In: Sadock BJ, Sadock VA, editors. Kaplan and Sadock's Comprehensive Textbook of Psychiatry. 7th edn . Lippincott Williams & Wilkins; 2000. pp. 1284­440.

03/02/2015 Reboxetine: A Novel Antidepressant Kadhe N G, Chillar A J, Deshmukh Y A ­ JPUBMED ] [ FULLTEXT ] 6. Holm KJ, Spencer CM. Reboxetine A Review of its Use in Depression. CNS Drugs 1999;12:65­83. 7. Martin Dale. The complete drug reference. Parfitt K, editor. 32nd edn. Pharmaceutical Press; 1999. pp. 307. 8. Montgomery SA. Chairman's overview. The place of reboxetine in antidepressant therapy. J Clin Psychiatry 1998;59:26­9. [ PUBMED ] 9. Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: a double­blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999;14:73­80. [ PUBMED ] 10. Venditti LN, Arcelus A, Birnbaum H, Greenberg P, Barr CE, RowlandC, et al. The impact of antidepressant use on social functioning: reboxetine versus fluoxetine. Int Clin Psychopharmacol 2000;15:279­89. 11. Berzewski H, Van Moffaert M, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double­ blind study in patients suffering from major depressive offsodes. Eur Neuropsychopharmacol 1997;Suppl 1:S37­47; (discussion S71­3). 12. Tanum L Reboxetine: tolerability and safety profile in patients with major depression. Acta Psychiatr Scand Suppl 2000;402:37­40. 13. AndreoliV, Carbognin G, Abati A , Vantini G. Reboxetine in the treatment of depression in the elderly: pilot study. J Geriatr Psychiatry Neurol 1999;12:206­10. 14. Larrosa O, de la Llave Y, Bario S,Granizo JJ, Garcia­Borreguero D. Stimulant and anti cataplectic effects of reboxetine in patients with narcolepsy: a pilot study Sleep 2001;24:282­5. 15. Dannon PN, Iancu I, Grunhaus L. The efficacy of reboxetine in the treatment ­refractory patients with panic disorder: an open label study. Human Psychopharmacol 2002;17:329­33. 16. Lemke MR. Effect of reboxetine on depression in Parkinson's disease patients. J Clin Psychiatry 2002;63:300­4. 17. Healy D. Reboxetine: its effects as measured by the Social Adaptation Self evaluation Scale. Acta Psychiatr Scand Suppl 2000;402: 18. 45­51. [ PUBMED ] 19. Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: http://www.jpgmonline.com/article.asp?issn=0022­3859;year=2003;volume=49;issue=4;spage=373;epage=375;aulast=Kadhe 6/8 " id="pdf-obj-5-14" src="pdf-obj-5-14.jpg">
  • 2. De Battista C, Schatzberg AF. Other Biological and Pharmacological therapies In: Sadock BJ, Sadock VA, editors. Kaplan and Sadock's Comprehensive Textbook of Psychiatry. 7th edn . Lippincott Williams & Wilkins; 2000. pp. 2527.

  • 3. Zydus Neurosciences. Narebox. Product Monograph.

03/02/2015 Reboxetine: A Novel Antidepressant Kadhe N G, Chillar A J, Deshmukh Y A ­ JPUBMED ] [ FULLTEXT ] 6. Holm KJ, Spencer CM. Reboxetine A Review of its Use in Depression. CNS Drugs 1999;12:65­83. 7. Martin Dale. The complete drug reference. Parfitt K, editor. 32nd edn. Pharmaceutical Press; 1999. pp. 307. 8. Montgomery SA. Chairman's overview. The place of reboxetine in antidepressant therapy. J Clin Psychiatry 1998;59:26­9. [ PUBMED ] 9. Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: a double­blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999;14:73­80. [ PUBMED ] 10. Venditti LN, Arcelus A, Birnbaum H, Greenberg P, Barr CE, RowlandC, et al. The impact of antidepressant use on social functioning: reboxetine versus fluoxetine. Int Clin Psychopharmacol 2000;15:279­89. 11. Berzewski H, Van Moffaert M, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double­ blind study in patients suffering from major depressive offsodes. Eur Neuropsychopharmacol 1997;Suppl 1:S37­47; (discussion S71­3). 12. Tanum L Reboxetine: tolerability and safety profile in patients with major depression. Acta Psychiatr Scand Suppl 2000;402:37­40. 13. AndreoliV, Carbognin G, Abati A , Vantini G. Reboxetine in the treatment of depression in the elderly: pilot study. J Geriatr Psychiatry Neurol 1999;12:206­10. 14. Larrosa O, de la Llave Y, Bario S,Granizo JJ, Garcia­Borreguero D. Stimulant and anti cataplectic effects of reboxetine in patients with narcolepsy: a pilot study Sleep 2001;24:282­5. 15. Dannon PN, Iancu I, Grunhaus L. The efficacy of reboxetine in the treatment ­refractory patients with panic disorder: an open label study. Human Psychopharmacol 2002;17:329­33. 16. Lemke MR. Effect of reboxetine on depression in Parkinson's disease patients. J Clin Psychiatry 2002;63:300­4. 17. Healy D. Reboxetine: its effects as measured by the Social Adaptation Self evaluation Scale. Acta Psychiatr Scand Suppl 2000;402: 18. 45­51. [ PUBMED ] 19. Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: http://www.jpgmonline.com/article.asp?issn=0022­3859;year=2003;volume=49;issue=4;spage=373;epage=375;aulast=Kadhe 6/8 " id="pdf-obj-5-22" src="pdf-obj-5-22.jpg">
  • 4. Delgado PL, Moreno FA. Role of norepinephrine in depression. J Clin Psychiatry 2000;61:5­12.

03/02/2015 Reboxetine: A Novel Antidepressant Kadhe N G, Chillar A J, Deshmukh Y A ­ JPUBMED ] [ FULLTEXT ] 6. Holm KJ, Spencer CM. Reboxetine A Review of its Use in Depression. CNS Drugs 1999;12:65­83. 7. Martin Dale. The complete drug reference. Parfitt K, editor. 32nd edn. Pharmaceutical Press; 1999. pp. 307. 8. Montgomery SA. Chairman's overview. The place of reboxetine in antidepressant therapy. J Clin Psychiatry 1998;59:26­9. [ PUBMED ] 9. Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: a double­blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999;14:73­80. [ PUBMED ] 10. Venditti LN, Arcelus A, Birnbaum H, Greenberg P, Barr CE, RowlandC, et al. The impact of antidepressant use on social functioning: reboxetine versus fluoxetine. Int Clin Psychopharmacol 2000;15:279­89. 11. Berzewski H, Van Moffaert M, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double­ blind study in patients suffering from major depressive offsodes. Eur Neuropsychopharmacol 1997;Suppl 1:S37­47; (discussion S71­3). 12. Tanum L Reboxetine: tolerability and safety profile in patients with major depression. Acta Psychiatr Scand Suppl 2000;402:37­40. 13. AndreoliV, Carbognin G, Abati A , Vantini G. Reboxetine in the treatment of depression in the elderly: pilot study. J Geriatr Psychiatry Neurol 1999;12:206­10. 14. Larrosa O, de la Llave Y, Bario S,Granizo JJ, Garcia­Borreguero D. Stimulant and anti cataplectic effects of reboxetine in patients with narcolepsy: a pilot study Sleep 2001;24:282­5. 15. Dannon PN, Iancu I, Grunhaus L. The efficacy of reboxetine in the treatment ­refractory patients with panic disorder: an open label study. Human Psychopharmacol 2002;17:329­33. 16. Lemke MR. Effect of reboxetine on depression in Parkinson's disease patients. J Clin Psychiatry 2002;63:300­4. 17. Healy D. Reboxetine: its effects as measured by the Social Adaptation Self evaluation Scale. Acta Psychiatr Scand Suppl 2000;402: 18. 45­51. [ PUBMED ] 19. Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: http://www.jpgmonline.com/article.asp?issn=0022­3859;year=2003;volume=49;issue=4;spage=373;epage=375;aulast=Kadhe 6/8 " id="pdf-obj-5-27" src="pdf-obj-5-27.jpg">
  • 5. Kent JM. SNaRIs, NaSSAs and NaRIs: new agents for the treatment of depression. Lancet 2000;355:911­8.

03/02/2015 Reboxetine: A Novel Antidepressant Kadhe N G, Chillar A J, Deshmukh Y A ­ JPUBMED ] [ FULLTEXT ] 6. Holm KJ, Spencer CM. Reboxetine A Review of its Use in Depression. CNS Drugs 1999;12:65­83. 7. Martin Dale. The complete drug reference. Parfitt K, editor. 32nd edn. Pharmaceutical Press; 1999. pp. 307. 8. Montgomery SA. Chairman's overview. The place of reboxetine in antidepressant therapy. J Clin Psychiatry 1998;59:26­9. [ PUBMED ] 9. Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: a double­blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999;14:73­80. [ PUBMED ] 10. Venditti LN, Arcelus A, Birnbaum H, Greenberg P, Barr CE, RowlandC, et al. The impact of antidepressant use on social functioning: reboxetine versus fluoxetine. Int Clin Psychopharmacol 2000;15:279­89. 11. Berzewski H, Van Moffaert M, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double­ blind study in patients suffering from major depressive offsodes. Eur Neuropsychopharmacol 1997;Suppl 1:S37­47; (discussion S71­3). 12. Tanum L Reboxetine: tolerability and safety profile in patients with major depression. Acta Psychiatr Scand Suppl 2000;402:37­40. 13. AndreoliV, Carbognin G, Abati A , Vantini G. Reboxetine in the treatment of depression in the elderly: pilot study. J Geriatr Psychiatry Neurol 1999;12:206­10. 14. Larrosa O, de la Llave Y, Bario S,Granizo JJ, Garcia­Borreguero D. Stimulant and anti cataplectic effects of reboxetine in patients with narcolepsy: a pilot study Sleep 2001;24:282­5. 15. Dannon PN, Iancu I, Grunhaus L. The efficacy of reboxetine in the treatment ­refractory patients with panic disorder: an open label study. Human Psychopharmacol 2002;17:329­33. 16. Lemke MR. Effect of reboxetine on depression in Parkinson's disease patients. J Clin Psychiatry 2002;63:300­4. 17. Healy D. Reboxetine: its effects as measured by the Social Adaptation Self evaluation Scale. Acta Psychiatr Scand Suppl 2000;402: 18. 45­51. [ PUBMED ] 19. Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: http://www.jpgmonline.com/article.asp?issn=0022­3859;year=2003;volume=49;issue=4;spage=373;epage=375;aulast=Kadhe 6/8 " id="pdf-obj-5-32" src="pdf-obj-5-32.jpg">
  • 6. Holm KJ, Spencer CM. Reboxetine A Review of its Use in Depression. CNS Drugs 1999;12:65­83.

03/02/2015 Reboxetine: A Novel Antidepressant Kadhe N G, Chillar A J, Deshmukh Y A ­ JPUBMED ] [ FULLTEXT ] 6. Holm KJ, Spencer CM. Reboxetine A Review of its Use in Depression. CNS Drugs 1999;12:65­83. 7. Martin Dale. The complete drug reference. Parfitt K, editor. 32nd edn. Pharmaceutical Press; 1999. pp. 307. 8. Montgomery SA. Chairman's overview. The place of reboxetine in antidepressant therapy. J Clin Psychiatry 1998;59:26­9. [ PUBMED ] 9. Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: a double­blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999;14:73­80. [ PUBMED ] 10. Venditti LN, Arcelus A, Birnbaum H, Greenberg P, Barr CE, RowlandC, et al. The impact of antidepressant use on social functioning: reboxetine versus fluoxetine. Int Clin Psychopharmacol 2000;15:279­89. 11. Berzewski H, Van Moffaert M, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double­ blind study in patients suffering from major depressive offsodes. Eur Neuropsychopharmacol 1997;Suppl 1:S37­47; (discussion S71­3). 12. Tanum L Reboxetine: tolerability and safety profile in patients with major depression. Acta Psychiatr Scand Suppl 2000;402:37­40. 13. AndreoliV, Carbognin G, Abati A , Vantini G. Reboxetine in the treatment of depression in the elderly: pilot study. J Geriatr Psychiatry Neurol 1999;12:206­10. 14. Larrosa O, de la Llave Y, Bario S,Granizo JJ, Garcia­Borreguero D. Stimulant and anti cataplectic effects of reboxetine in patients with narcolepsy: a pilot study Sleep 2001;24:282­5. 15. Dannon PN, Iancu I, Grunhaus L. The efficacy of reboxetine in the treatment ­refractory patients with panic disorder: an open label study. Human Psychopharmacol 2002;17:329­33. 16. Lemke MR. Effect of reboxetine on depression in Parkinson's disease patients. J Clin Psychiatry 2002;63:300­4. 17. Healy D. Reboxetine: its effects as measured by the Social Adaptation Self evaluation Scale. Acta Psychiatr Scand Suppl 2000;402: 18. 45­51. [ PUBMED ] 19. Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: http://www.jpgmonline.com/article.asp?issn=0022­3859;year=2003;volume=49;issue=4;spage=373;epage=375;aulast=Kadhe 6/8 " id="pdf-obj-5-44" src="pdf-obj-5-44.jpg">
  • 7. Martin Dale. The complete drug reference. Parfitt K, editor. 32nd edn. Pharmaceutical Press; 1999. pp. 307.

03/02/2015 Reboxetine: A Novel Antidepressant Kadhe N G, Chillar A J, Deshmukh Y A ­ JPUBMED ] [ FULLTEXT ] 6. Holm KJ, Spencer CM. Reboxetine A Review of its Use in Depression. CNS Drugs 1999;12:65­83. 7. Martin Dale. The complete drug reference. Parfitt K, editor. 32nd edn. Pharmaceutical Press; 1999. pp. 307. 8. Montgomery SA. Chairman's overview. The place of reboxetine in antidepressant therapy. J Clin Psychiatry 1998;59:26­9. [ PUBMED ] 9. Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: a double­blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999;14:73­80. [ PUBMED ] 10. Venditti LN, Arcelus A, Birnbaum H, Greenberg P, Barr CE, RowlandC, et al. The impact of antidepressant use on social functioning: reboxetine versus fluoxetine. Int Clin Psychopharmacol 2000;15:279­89. 11. Berzewski H, Van Moffaert M, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double­ blind study in patients suffering from major depressive offsodes. Eur Neuropsychopharmacol 1997;Suppl 1:S37­47; (discussion S71­3). 12. Tanum L Reboxetine: tolerability and safety profile in patients with major depression. Acta Psychiatr Scand Suppl 2000;402:37­40. 13. AndreoliV, Carbognin G, Abati A , Vantini G. Reboxetine in the treatment of depression in the elderly: pilot study. J Geriatr Psychiatry Neurol 1999;12:206­10. 14. Larrosa O, de la Llave Y, Bario S,Granizo JJ, Garcia­Borreguero D. Stimulant and anti cataplectic effects of reboxetine in patients with narcolepsy: a pilot study Sleep 2001;24:282­5. 15. Dannon PN, Iancu I, Grunhaus L. The efficacy of reboxetine in the treatment ­refractory patients with panic disorder: an open label study. Human Psychopharmacol 2002;17:329­33. 16. Lemke MR. Effect of reboxetine on depression in Parkinson's disease patients. J Clin Psychiatry 2002;63:300­4. 17. Healy D. Reboxetine: its effects as measured by the Social Adaptation Self evaluation Scale. Acta Psychiatr Scand Suppl 2000;402: 18. 45­51. [ PUBMED ] 19. Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: http://www.jpgmonline.com/article.asp?issn=0022­3859;year=2003;volume=49;issue=4;spage=373;epage=375;aulast=Kadhe 6/8 " id="pdf-obj-5-49" src="pdf-obj-5-49.jpg">
  • 8. Montgomery SA. Chairman's overview. The place of reboxetine in antidepressant therapy. J Clin Psychiatry 1998;59:26­9.

03/02/2015 Reboxetine: A Novel Antidepressant Kadhe N G, Chillar A J, Deshmukh Y A ­ JPUBMED ] [ FULLTEXT ] 6. Holm KJ, Spencer CM. Reboxetine A Review of its Use in Depression. CNS Drugs 1999;12:65­83. 7. Martin Dale. The complete drug reference. Parfitt K, editor. 32nd edn. Pharmaceutical Press; 1999. pp. 307. 8. Montgomery SA. Chairman's overview. The place of reboxetine in antidepressant therapy. J Clin Psychiatry 1998;59:26­9. [ PUBMED ] 9. Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: a double­blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999;14:73­80. [ PUBMED ] 10. Venditti LN, Arcelus A, Birnbaum H, Greenberg P, Barr CE, RowlandC, et al. The impact of antidepressant use on social functioning: reboxetine versus fluoxetine. Int Clin Psychopharmacol 2000;15:279­89. 11. Berzewski H, Van Moffaert M, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double­ blind study in patients suffering from major depressive offsodes. Eur Neuropsychopharmacol 1997;Suppl 1:S37­47; (discussion S71­3). 12. Tanum L Reboxetine: tolerability and safety profile in patients with major depression. Acta Psychiatr Scand Suppl 2000;402:37­40. 13. AndreoliV, Carbognin G, Abati A , Vantini G. Reboxetine in the treatment of depression in the elderly: pilot study. J Geriatr Psychiatry Neurol 1999;12:206­10. 14. Larrosa O, de la Llave Y, Bario S,Granizo JJ, Garcia­Borreguero D. Stimulant and anti cataplectic effects of reboxetine in patients with narcolepsy: a pilot study Sleep 2001;24:282­5. 15. Dannon PN, Iancu I, Grunhaus L. The efficacy of reboxetine in the treatment ­refractory patients with panic disorder: an open label study. Human Psychopharmacol 2002;17:329­33. 16. Lemke MR. Effect of reboxetine on depression in Parkinson's disease patients. J Clin Psychiatry 2002;63:300­4. 17. Healy D. Reboxetine: its effects as measured by the Social Adaptation Self evaluation Scale. Acta Psychiatr Scand Suppl 2000;402: 18. 45­51. [ PUBMED ] 19. Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: http://www.jpgmonline.com/article.asp?issn=0022­3859;year=2003;volume=49;issue=4;spage=373;epage=375;aulast=Kadhe 6/8 " id="pdf-obj-5-58" src="pdf-obj-5-58.jpg">
  • 9. Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: a double­blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999;14:73­80.

03/02/2015 Reboxetine: A Novel Antidepressant Kadhe N G, Chillar A J, Deshmukh Y A ­ JPUBMED ] [ FULLTEXT ] 6. Holm KJ, Spencer CM. Reboxetine A Review of its Use in Depression. CNS Drugs 1999;12:65­83. 7. Martin Dale. The complete drug reference. Parfitt K, editor. 32nd edn. Pharmaceutical Press; 1999. pp. 307. 8. Montgomery SA. Chairman's overview. The place of reboxetine in antidepressant therapy. J Clin Psychiatry 1998;59:26­9. [ PUBMED ] 9. Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: a double­blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999;14:73­80. [ PUBMED ] 10. Venditti LN, Arcelus A, Birnbaum H, Greenberg P, Barr CE, RowlandC, et al. The impact of antidepressant use on social functioning: reboxetine versus fluoxetine. Int Clin Psychopharmacol 2000;15:279­89. 11. Berzewski H, Van Moffaert M, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double­ blind study in patients suffering from major depressive offsodes. Eur Neuropsychopharmacol 1997;Suppl 1:S37­47; (discussion S71­3). 12. Tanum L Reboxetine: tolerability and safety profile in patients with major depression. Acta Psychiatr Scand Suppl 2000;402:37­40. 13. AndreoliV, Carbognin G, Abati A , Vantini G. Reboxetine in the treatment of depression in the elderly: pilot study. J Geriatr Psychiatry Neurol 1999;12:206­10. 14. Larrosa O, de la Llave Y, Bario S,Granizo JJ, Garcia­Borreguero D. Stimulant and anti cataplectic effects of reboxetine in patients with narcolepsy: a pilot study Sleep 2001;24:282­5. 15. Dannon PN, Iancu I, Grunhaus L. The efficacy of reboxetine in the treatment ­refractory patients with panic disorder: an open label study. Human Psychopharmacol 2002;17:329­33. 16. Lemke MR. Effect of reboxetine on depression in Parkinson's disease patients. J Clin Psychiatry 2002;63:300­4. 17. Healy D. Reboxetine: its effects as measured by the Social Adaptation Self evaluation Scale. Acta Psychiatr Scand Suppl 2000;402: 18. 45­51. [ PUBMED ] 19. Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: http://www.jpgmonline.com/article.asp?issn=0022­3859;year=2003;volume=49;issue=4;spage=373;epage=375;aulast=Kadhe 6/8 " id="pdf-obj-5-67" src="pdf-obj-5-67.jpg">

10.Venditti LN, Arcelus A, Birnbaum H, Greenberg P, Barr CE,

RowlandC, et al. The impact of antidepressant use on social

functioning: reboxetine versus fluoxetine. Int Clin

Psychopharmacol 2000;15:279­89.

03/02/2015 Reboxetine: A Novel Antidepressant Kadhe N G, Chillar A J, Deshmukh Y A ­ JPUBMED ] [ FULLTEXT ] 6. Holm KJ, Spencer CM. Reboxetine A Review of its Use in Depression. CNS Drugs 1999;12:65­83. 7. Martin Dale. The complete drug reference. Parfitt K, editor. 32nd edn. Pharmaceutical Press; 1999. pp. 307. 8. Montgomery SA. Chairman's overview. The place of reboxetine in antidepressant therapy. J Clin Psychiatry 1998;59:26­9. [ PUBMED ] 9. Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: a double­blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999;14:73­80. [ PUBMED ] 10. Venditti LN, Arcelus A, Birnbaum H, Greenberg P, Barr CE, RowlandC, et al. The impact of antidepressant use on social functioning: reboxetine versus fluoxetine. Int Clin Psychopharmacol 2000;15:279­89. 11. Berzewski H, Van Moffaert M, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double­ blind study in patients suffering from major depressive offsodes. Eur Neuropsychopharmacol 1997;Suppl 1:S37­47; (discussion S71­3). 12. Tanum L Reboxetine: tolerability and safety profile in patients with major depression. Acta Psychiatr Scand Suppl 2000;402:37­40. 13. AndreoliV, Carbognin G, Abati A , Vantini G. Reboxetine in the treatment of depression in the elderly: pilot study. J Geriatr Psychiatry Neurol 1999;12:206­10. 14. Larrosa O, de la Llave Y, Bario S,Granizo JJ, Garcia­Borreguero D. Stimulant and anti cataplectic effects of reboxetine in patients with narcolepsy: a pilot study Sleep 2001;24:282­5. 15. Dannon PN, Iancu I, Grunhaus L. The efficacy of reboxetine in the treatment ­refractory patients with panic disorder: an open label study. Human Psychopharmacol 2002;17:329­33. 16. Lemke MR. Effect of reboxetine on depression in Parkinson's disease patients. J Clin Psychiatry 2002;63:300­4. 17. Healy D. Reboxetine: its effects as measured by the Social Adaptation Self evaluation Scale. Acta Psychiatr Scand Suppl 2000;402: 18. 45­51. [ PUBMED ] 19. Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: http://www.jpgmonline.com/article.asp?issn=0022­3859;year=2003;volume=49;issue=4;spage=373;epage=375;aulast=Kadhe 6/8 " id="pdf-obj-5-78" src="pdf-obj-5-78.jpg">

11.Berzewski H, Van Moffaert M, Gagiano CA. Efficacy and

tolerability of reboxetine compared with imipramine in a double­

blind study in patients suffering from major depressive offsodes.

Eur Neuropsychopharmacol 1997;Suppl 1:S37­47; (discussion

S71­3).

03/02/2015 Reboxetine: A Novel Antidepressant Kadhe N G, Chillar A J, Deshmukh Y A ­ JPUBMED ] [ FULLTEXT ] 6. Holm KJ, Spencer CM. Reboxetine A Review of its Use in Depression. CNS Drugs 1999;12:65­83. 7. Martin Dale. The complete drug reference. Parfitt K, editor. 32nd edn. Pharmaceutical Press; 1999. pp. 307. 8. Montgomery SA. Chairman's overview. The place of reboxetine in antidepressant therapy. J Clin Psychiatry 1998;59:26­9. [ PUBMED ] 9. Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: a double­blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999;14:73­80. [ PUBMED ] 10. Venditti LN, Arcelus A, Birnbaum H, Greenberg P, Barr CE, RowlandC, et al. The impact of antidepressant use on social functioning: reboxetine versus fluoxetine. Int Clin Psychopharmacol 2000;15:279­89. 11. Berzewski H, Van Moffaert M, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double­ blind study in patients suffering from major depressive offsodes. Eur Neuropsychopharmacol 1997;Suppl 1:S37­47; (discussion S71­3). 12. Tanum L Reboxetine: tolerability and safety profile in patients with major depression. Acta Psychiatr Scand Suppl 2000;402:37­40. 13. AndreoliV, Carbognin G, Abati A , Vantini G. Reboxetine in the treatment of depression in the elderly: pilot study. J Geriatr Psychiatry Neurol 1999;12:206­10. 14. Larrosa O, de la Llave Y, Bario S,Granizo JJ, Garcia­Borreguero D. Stimulant and anti cataplectic effects of reboxetine in patients with narcolepsy: a pilot study Sleep 2001;24:282­5. 15. Dannon PN, Iancu I, Grunhaus L. The efficacy of reboxetine in the treatment ­refractory patients with panic disorder: an open label study. Human Psychopharmacol 2002;17:329­33. 16. Lemke MR. Effect of reboxetine on depression in Parkinson's disease patients. J Clin Psychiatry 2002;63:300­4. 17. Healy D. Reboxetine: its effects as measured by the Social Adaptation Self evaluation Scale. Acta Psychiatr Scand Suppl 2000;402: 18. 45­51. [ PUBMED ] 19. Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: http://www.jpgmonline.com/article.asp?issn=0022­3859;year=2003;volume=49;issue=4;spage=373;epage=375;aulast=Kadhe 6/8 " id="pdf-obj-5-91" src="pdf-obj-5-91.jpg">

12.Tanum L Reboxetine: tolerability and safety profile in patients with

major depression. Acta Psychiatr Scand Suppl 2000;402:37­40.

03/02/2015 Reboxetine: A Novel Antidepressant Kadhe N G, Chillar A J, Deshmukh Y A ­ JPUBMED ] [ FULLTEXT ] 6. Holm KJ, Spencer CM. Reboxetine A Review of its Use in Depression. CNS Drugs 1999;12:65­83. 7. Martin Dale. The complete drug reference. Parfitt K, editor. 32nd edn. Pharmaceutical Press; 1999. pp. 307. 8. Montgomery SA. Chairman's overview. The place of reboxetine in antidepressant therapy. J Clin Psychiatry 1998;59:26­9. [ PUBMED ] 9. Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: a double­blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999;14:73­80. [ PUBMED ] 10. Venditti LN, Arcelus A, Birnbaum H, Greenberg P, Barr CE, RowlandC, et al. The impact of antidepressant use on social functioning: reboxetine versus fluoxetine. Int Clin Psychopharmacol 2000;15:279­89. 11. Berzewski H, Van Moffaert M, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double­ blind study in patients suffering from major depressive offsodes. Eur Neuropsychopharmacol 1997;Suppl 1:S37­47; (discussion S71­3). 12. Tanum L Reboxetine: tolerability and safety profile in patients with major depression. Acta Psychiatr Scand Suppl 2000;402:37­40. 13. AndreoliV, Carbognin G, Abati A , Vantini G. Reboxetine in the treatment of depression in the elderly: pilot study. J Geriatr Psychiatry Neurol 1999;12:206­10. 14. Larrosa O, de la Llave Y, Bario S,Granizo JJ, Garcia­Borreguero D. Stimulant and anti cataplectic effects of reboxetine in patients with narcolepsy: a pilot study Sleep 2001;24:282­5. 15. Dannon PN, Iancu I, Grunhaus L. The efficacy of reboxetine in the treatment ­refractory patients with panic disorder: an open label study. Human Psychopharmacol 2002;17:329­33. 16. Lemke MR. Effect of reboxetine on depression in Parkinson's disease patients. J Clin Psychiatry 2002;63:300­4. 17. Healy D. Reboxetine: its effects as measured by the Social Adaptation Self evaluation Scale. Acta Psychiatr Scand Suppl 2000;402: 18. 45­51. [ PUBMED ] 19. Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: http://www.jpgmonline.com/article.asp?issn=0022­3859;year=2003;volume=49;issue=4;spage=373;epage=375;aulast=Kadhe 6/8 " id="pdf-obj-5-98" src="pdf-obj-5-98.jpg">

13.AndreoliV, Carbognin G, Abati A , Vantini G. Reboxetine in the

treatment of depression in the elderly: pilot study. J Geriatr

Psychiatry Neurol 1999;12:206­10.

03/02/2015 Reboxetine: A Novel Antidepressant Kadhe N G, Chillar A J, Deshmukh Y A ­ JPUBMED ] [ FULLTEXT ] 6. Holm KJ, Spencer CM. Reboxetine A Review of its Use in Depression. CNS Drugs 1999;12:65­83. 7. Martin Dale. The complete drug reference. Parfitt K, editor. 32nd edn. Pharmaceutical Press; 1999. pp. 307. 8. Montgomery SA. Chairman's overview. The place of reboxetine in antidepressant therapy. J Clin Psychiatry 1998;59:26­9. [ PUBMED ] 9. Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: a double­blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999;14:73­80. [ PUBMED ] 10. Venditti LN, Arcelus A, Birnbaum H, Greenberg P, Barr CE, RowlandC, et al. The impact of antidepressant use on social functioning: reboxetine versus fluoxetine. Int Clin Psychopharmacol 2000;15:279­89. 11. Berzewski H, Van Moffaert M, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double­ blind study in patients suffering from major depressive offsodes. Eur Neuropsychopharmacol 1997;Suppl 1:S37­47; (discussion S71­3). 12. Tanum L Reboxetine: tolerability and safety profile in patients with major depression. Acta Psychiatr Scand Suppl 2000;402:37­40. 13. AndreoliV, Carbognin G, Abati A , Vantini G. Reboxetine in the treatment of depression in the elderly: pilot study. J Geriatr Psychiatry Neurol 1999;12:206­10. 14. Larrosa O, de la Llave Y, Bario S,Granizo JJ, Garcia­Borreguero D. Stimulant and anti cataplectic effects of reboxetine in patients with narcolepsy: a pilot study Sleep 2001;24:282­5. 15. Dannon PN, Iancu I, Grunhaus L. The efficacy of reboxetine in the treatment ­refractory patients with panic disorder: an open label study. Human Psychopharmacol 2002;17:329­33. 16. Lemke MR. Effect of reboxetine on depression in Parkinson's disease patients. J Clin Psychiatry 2002;63:300­4. 17. Healy D. Reboxetine: its effects as measured by the Social Adaptation Self evaluation Scale. Acta Psychiatr Scand Suppl 2000;402: 18. 45­51. [ PUBMED ] 19. Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: http://www.jpgmonline.com/article.asp?issn=0022­3859;year=2003;volume=49;issue=4;spage=373;epage=375;aulast=Kadhe 6/8 " id="pdf-obj-5-107" src="pdf-obj-5-107.jpg">

14.Larrosa O, de la Llave Y, Bario S,Granizo JJ, Garcia­Borreguero

D. Stimulant and anti cataplectic effects of reboxetine in patients

with narcolepsy: a pilot study Sleep 2001;24:282­5.

03/02/2015 Reboxetine: A Novel Antidepressant Kadhe N G, Chillar A J, Deshmukh Y A ­ JPUBMED ] [ FULLTEXT ] 6. Holm KJ, Spencer CM. Reboxetine A Review of its Use in Depression. CNS Drugs 1999;12:65­83. 7. Martin Dale. The complete drug reference. Parfitt K, editor. 32nd edn. Pharmaceutical Press; 1999. pp. 307. 8. Montgomery SA. Chairman's overview. The place of reboxetine in antidepressant therapy. J Clin Psychiatry 1998;59:26­9. [ PUBMED ] 9. Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: a double­blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999;14:73­80. [ PUBMED ] 10. Venditti LN, Arcelus A, Birnbaum H, Greenberg P, Barr CE, RowlandC, et al. The impact of antidepressant use on social functioning: reboxetine versus fluoxetine. Int Clin Psychopharmacol 2000;15:279­89. 11. Berzewski H, Van Moffaert M, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double­ blind study in patients suffering from major depressive offsodes. Eur Neuropsychopharmacol 1997;Suppl 1:S37­47; (discussion S71­3). 12. Tanum L Reboxetine: tolerability and safety profile in patients with major depression. Acta Psychiatr Scand Suppl 2000;402:37­40. 13. AndreoliV, Carbognin G, Abati A , Vantini G. Reboxetine in the treatment of depression in the elderly: pilot study. J Geriatr Psychiatry Neurol 1999;12:206­10. 14. Larrosa O, de la Llave Y, Bario S,Granizo JJ, Garcia­Borreguero D. Stimulant and anti cataplectic effects of reboxetine in patients with narcolepsy: a pilot study Sleep 2001;24:282­5. 15. Dannon PN, Iancu I, Grunhaus L. The efficacy of reboxetine in the treatment ­refractory patients with panic disorder: an open label study. Human Psychopharmacol 2002;17:329­33. 16. Lemke MR. Effect of reboxetine on depression in Parkinson's disease patients. J Clin Psychiatry 2002;63:300­4. 17. Healy D. Reboxetine: its effects as measured by the Social Adaptation Self evaluation Scale. Acta Psychiatr Scand Suppl 2000;402: 18. 45­51. [ PUBMED ] 19. Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: http://www.jpgmonline.com/article.asp?issn=0022­3859;year=2003;volume=49;issue=4;spage=373;epage=375;aulast=Kadhe 6/8 " id="pdf-obj-5-116" src="pdf-obj-5-116.jpg">

15.Dannon PN, Iancu I, Grunhaus L. The efficacy of reboxetine in the

treatment ­refractory patients with panic disorder: an open label

study. Human Psychopharmacol 2002;17:329­33.

study. Human Psychopharmacol 2002;17:329­33.

16.Lemke MR. Effect of reboxetine on depression in Parkinson's

disease patients. J Clin Psychiatry 2002;63:300­4.

disease patients. J Clin Psychiatry 2002;63:300­4.

17.Healy D. Reboxetine: its effects as measured by the Social

Adaptation Self evaluation Scale. Acta Psychiatr Scand Suppl

2000;402:

03/02/2015 Reboxetine: A Novel Antidepressant Kadhe N G, Chillar A J, Deshmukh Y A ­ JPUBMED ] [ FULLTEXT ] 6. Holm KJ, Spencer CM. Reboxetine A Review of its Use in Depression. CNS Drugs 1999;12:65­83. 7. Martin Dale. The complete drug reference. Parfitt K, editor. 32nd edn. Pharmaceutical Press; 1999. pp. 307. 8. Montgomery SA. Chairman's overview. The place of reboxetine in antidepressant therapy. J Clin Psychiatry 1998;59:26­9. [ PUBMED ] 9. Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: a double­blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999;14:73­80. [ PUBMED ] 10. Venditti LN, Arcelus A, Birnbaum H, Greenberg P, Barr CE, RowlandC, et al. The impact of antidepressant use on social functioning: reboxetine versus fluoxetine. Int Clin Psychopharmacol 2000;15:279­89. 11. Berzewski H, Van Moffaert M, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double­ blind study in patients suffering from major depressive offsodes. Eur Neuropsychopharmacol 1997;Suppl 1:S37­47; (discussion S71­3). 12. Tanum L Reboxetine: tolerability and safety profile in patients with major depression. Acta Psychiatr Scand Suppl 2000;402:37­40. 13. AndreoliV, Carbognin G, Abati A , Vantini G. Reboxetine in the treatment of depression in the elderly: pilot study. J Geriatr Psychiatry Neurol 1999;12:206­10. 14. Larrosa O, de la Llave Y, Bario S,Granizo JJ, Garcia­Borreguero D. Stimulant and anti cataplectic effects of reboxetine in patients with narcolepsy: a pilot study Sleep 2001;24:282­5. 15. Dannon PN, Iancu I, Grunhaus L. The efficacy of reboxetine in the treatment ­refractory patients with panic disorder: an open label study. Human Psychopharmacol 2002;17:329­33. 16. Lemke MR. Effect of reboxetine on depression in Parkinson's disease patients. J Clin Psychiatry 2002;63:300­4. 17. Healy D. Reboxetine: its effects as measured by the Social Adaptation Self evaluation Scale. Acta Psychiatr Scand Suppl 2000;402: 18. 45­51. [ PUBMED ] 19. Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: http://www.jpgmonline.com/article.asp?issn=0022­3859;year=2003;volume=49;issue=4;spage=373;epage=375;aulast=Kadhe 6/8 " id="pdf-obj-5-146" src="pdf-obj-5-146.jpg">

18.45­51. [PUBMED]

19.Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine:

03/02/2015

Reboxetine: A Novel Antidepressant Kadhe N G, Chillar A J, Deshmukh Y A ­ J Postgrad Med

a double blind comparison with fluoxetine in major depressive

disorder. Int Clin Psychopharmacol 1999;14:73­80.

03/02/2015 Reboxetine: A Novel Antidepressant Kadhe N G, Chillar A J, Deshmukh Y A ­ J[Pubmed] Increased fetal blood pressure response to maternal 2 norepinephrine after pharmacological inhibition f norepinephrine uptake in pregnant sheep Hansson SR, Bottalico B, Amer­Wahlin I, et al. ACTA PAEDIATRICA. 2007; 96 (5): 650­654 [Pubmed] 3 Reboxetine may cause amenorrhea in female patients Yalug I, Tural U, Unsalan N, et al. INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE. 2006; 10 (3): 223­225 [Pubmed] Reboxetine may cause amenorrhea in female patients: a case report Yalug I, Tural U, Unsalan N, et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2005; 15: S412­S412 [Pubmed] Previous article Next article Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer Online since 12 February '04 © 2004 ­ 2015 Journal of Postgraduate Medicine Official Publication of the Staff Society of the Seth GS Medical College and KEM Hospital, Mumbai, India Published by Medknow                     htt p://www.jpgmonline.com/article.asp?issn=0022­3859;year=2003;volume=49;issue=4;spage=373;epage=375;aulast=Kadhe 7 /8 " id="pdf-obj-6-11" src="pdf-obj-6-11.jpg">

This article has been cited by

Inhibition of G­protein­activated inwardly rectifying K+

  • 1 channels by the selective norepinephrine reuptake inhibitors atomoxetine and reboxetine Kobayashi, T., Washiyama, K., Ikeda, K. Neuropsychopharmacology. 2010; 35(7): 1560­1569 [Pubmed] Increased fetal blood pressure response to maternal

  • 2 norepinephrine after pharmacological inhibition f norepinephrine uptake in pregnant sheep Hansson SR, Bottalico B, Amer­Wahlin I, et al. ACTA PAEDIATRICA. 2007; 96 (5): 650­654 [Pubmed]

  • 3 Reboxetine may cause amenorrhea in female patients Yalug I, Tural U, Unsalan N, et al. INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE. 2006; 10 (3): 223­225 [Pubmed]

  • 4 Reboxetine may cause amenorrhea in female patients: a case report Yalug I, Tural U, Unsalan N, et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2005; 15: S412­S412 [Pubmed]

03/02/2015 Reboxetine: A Novel Antidepressant Kadhe N G, Chillar A J, Deshmukh Y A ­ J[Pubmed] Increased fetal blood pressure response to maternal 2 norepinephrine after pharmacological inhibition f norepinephrine uptake in pregnant sheep Hansson SR, Bottalico B, Amer­Wahlin I, et al. ACTA PAEDIATRICA. 2007; 96 (5): 650­654 [Pubmed] 3 Reboxetine may cause amenorrhea in female patients Yalug I, Tural U, Unsalan N, et al. INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE. 2006; 10 (3): 223­225 [Pubmed] Reboxetine may cause amenorrhea in female patients: a case report Yalug I, Tural U, Unsalan N, et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2005; 15: S412­S412 [Pubmed] Previous article Next article Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer Online since 12 February '04 © 2004 ­ 2015 Journal of Postgraduate Medicine Official Publication of the Staff Society of the Seth GS Medical College and KEM Hospital, Mumbai, India Published by Medknow                     htt p://www.jpgmonline.com/article.asp?issn=0022­3859;year=2003;volume=49;issue=4;spage=373;epage=375;aulast=Kadhe 7 /8 " id="pdf-obj-6-39" src="pdf-obj-6-39.jpg">
03/02/2015 Reboxetine: A Novel Antidepressant Kadhe N G, Chillar A J, Deshmukh Y A ­ J[Pubmed] Increased fetal blood pressure response to maternal 2 norepinephrine after pharmacological inhibition f norepinephrine uptake in pregnant sheep Hansson SR, Bottalico B, Amer­Wahlin I, et al. ACTA PAEDIATRICA. 2007; 96 (5): 650­654 [Pubmed] 3 Reboxetine may cause amenorrhea in female patients Yalug I, Tural U, Unsalan N, et al. INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE. 2006; 10 (3): 223­225 [Pubmed] Reboxetine may cause amenorrhea in female patients: a case report Yalug I, Tural U, Unsalan N, et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2005; 15: S412­S412 [Pubmed] Previous article Next article Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer Online since 12 February '04 © 2004 ­ 2015 Journal of Postgraduate Medicine Official Publication of the Staff Society of the Seth GS Medical College and KEM Hospital, Mumbai, India Published by Medknow                     htt p://www.jpgmonline.com/article.asp?issn=0022­3859;year=2003;volume=49;issue=4;spage=373;epage=375;aulast=Kadhe 7 /8 " id="pdf-obj-6-41" src="pdf-obj-6-41.jpg">

Online since 12 th February '04

© 2004 ­ 2015 Journal of Postgraduate Medicine

Published by Medknow

03 <a href=/02/2015 Reboxetine: A Novel Antidepressant Kadhe N G, Chillar A J, Deshmukh Y A ­ J Postgrad Med ISSN : Print ­0022­3859, Online ­ 0972­2823 http://www.jpgmonline.com/article.asp?issn=0022­3859;year=2003;volume=49;issue=4;spage=373;epage=375;aulast=Kadhe 8/8 " id="pdf-obj-7-8" src="pdf-obj-7-8.jpg">

ISSN: Print ­0022­3859, Online ­ 0972­2823